The Determination of Alpha-fetoprotein, Golgi protein-73 and Glypican-3 Levels in Chronic Viral Hepatitis B Patients with Fibrosis in Baghdad Gastroenterology and Hepatology Hospital

Suhad Mohammed Mahmoud; Athraa Zaidan Hassan; Salah Mahdi Hassan; Safaa Abdulkareem Alwaysi

doi:10.54133/ajms.v8i2(Special).1401

Authors

Suhad Mohammed Mahmoud Department of Medical Laboratory Technicians, College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq https://orcid.org/0009-0009-2986-0948
Athraa Zaidan Hassan Department of Medical Laboratory Technicians, College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq
Salah Mahdi Hassan Department of Medical Laboratory Technicians, College of Health and Medical Techniques, Middle Technical University, Baghdad, Iraq
Safaa Abdulkareem Alwaysi Hepatology and Gastroenterology Teaching Hospital, Baghdad, Iraq

DOI:

https://doi.org/10.54133/ajms.v8i2(Special).1401

Keywords:

AFP, GP73, GPC3, Hepatitis B, Liver fibrosis

Abstract

Background: Chronic hepatitis B (CHB) infects the liver and is considered the leading cause of fibrosis and hepatocellular carcinoma (HCC). As liver biopsy is invasive, biomarkers that predict CHB noninvasively could affect the overall complication of this dreaded disease. Objective: The aim of this study was to evaluate the use of alpha-fetoprotein (AFP), Golgi protein-73 (GP73), and glypican-3 levels as new predictive biomarkers for assessing hepatitis B infection patients with fibrosis. Method: This study included 60 participants and classified 30 chronic hepatitis B patients with fibrosis and 30 apparently healthy subjects who served as controls. The liver function test was performed for all participants, in addition to serum levels of AFP, GP73, and GPC3 level by using the sandwich ELISA technique. Liver fibrosis was assessed using FibroScan. Results: The current study showed that GP73 and GPC3 levels were significantly elevated in the chronic hepatitis B with fibrosis group; furthermore, AFP levels were significantly different in the chronic hepatitis B with fibrosis group compared to the control group. Conclusions: The current study demonstrated that GP73 alone or in combination with GPC3 level can be considered as an effective biomarker for assessing fibrosis among patients with CHB.

Downloads

Download data is not yet available.

References

Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, et al. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50(7):785-794. doi: 10.1007/s00535-014-1010-7. DOI: https://doi.org/10.1007/s00535-014-1010-7

Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al . Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928. doi: 10.3748/wjg.v21.i13.3928. DOI: https://doi.org/10.3748/wjg.v21.i13.3928

Tong MJ, Huynh TT, Siripongsakun S, Chang PW, Tong LT, Ha YP, et al. Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. Hepatol Int. 2015;9:567-577. doi: 10.1007/s12072-015-9651-z. DOI: https://doi.org/10.1007/s12072-015-9651-z

Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36(12):1755-1764. doi: 10.1111/liv.13253. DOI: https://doi.org/10.1111/liv.13253

Hadziyannis E, Laras A. Viral biomarkers in chronic HBeAg negative HBV infection. Genes. 2018;9(10):469. doi: 10.3390/genes9100469. DOI: https://doi.org/10.3390/genes9100469

Yao M, Zhao J, Lu F. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget. 2016;7(4):3702. doi: 10.18632/oncotarget.6913. DOI: https://doi.org/10.18632/oncotarget.6913

Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, et al. Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Med Oncology. 2015;32:1-0. doi: 10.1007/s12032-014-0367-z. DOI: https://doi.org/10.1007/s12032-014-0367-z

Chien J, Liu J, Lee MH, Jen CL, Batrla‐Utermann R, Lu SN, et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. Journal of gastroenterology and hepatology. 2016 Dec;31(12):1971-7. doi: 10.1111/jgh.13422. DOI: https://doi.org/10.1111/jgh.13422

Liu YR, Lin BB, Zeng DW, Zhu YY, Chen J, Zheng Q, et al. Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. BMC Gastroenterol. 2014;14:1-8. doi: 10.1186/1471-230X-14-145. DOI: https://doi.org/10.1186/1471-230X-14-145

Wu Y, Ma J, Wang Y, Zhang Y, Hou Y, Zhang C, et al. Development of an alpha-fetoprotein and Golgi protein 73 multiplex detection assay using xMAP technology. Clinica Chimica Acta. 2018;482:209-214. doi.org/10.1016/j.cca.2018.03.039. DOI: https://doi.org/10.1016/j.cca.2018.03.039

Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, et al. Reappraisal of serum alpha‐foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35(1):232-239. doi: 10.1111/liv.12516. DOI: https://doi.org/10.1111/liv.12516

Li S, Li X, Xu A, Zhang B, He X, Chen H, et al. Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma. Mol Med Rep. 2018;17(3):4720-4728. doi: 10.3892/mmr.2018.8372. DOI: https://doi.org/10.3892/mmr.2018.8372

Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, et al. Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma. Medicine. 2019;98(11):e14827. doi: 10.1097/MD.0000000000014827. DOI: https://doi.org/10.1097/MD.0000000000014827

Tajiri H, Takano T, Tanaka H, Ushijima K, Inui A, Miyoshi Y, et al. Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha‐fetoprotein assessment. Cancer Med. 2016;5(11):3102-3110. doi: 10.1002/cam4.917. DOI: https://doi.org/10.1002/cam4.917

Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49(5):1602-1609. doi: 10.1002/hep.22843. DOI: https://doi.org/10.1002/hep.22843

Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:1-8. doi: 10.1186/2046-4053-2-37. DOI: https://doi.org/10.1186/2046-4053-2-37

Yamauchi N, Watanabe A, Hishinuma M, Ohashi KI, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathol. 2005;18(12):1591-1598. doi: 10.1038/modpathol.3800436. DOI: https://doi.org/10.1038/modpathol.3800436

Tseng CH, Hsu YC, Ho HJ, Nguyen MH, Wu CY. Increasing age and non-liver comorbidities in patients with chronic hepatitis B in Taiwan: a nationwide population-based analysis. Digest Dis. 2021;39(3):266-274. doi: 10.1159/000511585. DOI: https://doi.org/10.1159/000511585

Yotsuyanagi H, Kurosaki M, Yatsuhashi H, Lee IH. Brooks-Rooney C, Nguyen MH. Characteristics and healthcare costs in the aging hepatitis B population of Japan: a nationwide real-world analysis. Digest Dis. 2022;40(1):68-77. doi: 10.1159/000515854. DOI: https://doi.org/10.1159/000515854

Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. JAMA Network Open. 2020;3(4):e201844. doi:10.1001/jamanetworkopen.2020.1844. DOI: https://doi.org/10.1001/jamanetworkopen.2020.1844

Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999-2016 Hepatology. 2020;71(2):431–443. doi: 10.1002/hep.30831. DOI: https://doi.org/10.1002/hep.30831

Galle PR. Management of liver cancer. Digest Dis. 2016;34(4):438-439. doi: 10.1159/000444559. DOI: https://doi.org/10.1159/000444559

Cheng WQ, Guan SH, Zhang H, Yang K, Chen ZD, Shao XX. Value of serum alpha-fetoprotein in predicting liver fibrosis in patients with chronic hepatitis B. J Clin Hepatol. 2018;34(5):1015-1019. doi: 10.3969/j.issn.1001-5256.2018.05.018.

Feng L, Sun K, Zhang J, Feng G, Zhao Y. A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study. BMJ Open. 2015;5(9):e008032. doi: 10.1136/bmjopen-2015-008032. DOI: https://doi.org/10.1136/bmjopen-2015-008032

Güçlü E, Öğütlü A, Kösem M, Erkorkmaz Ü, Karabay O. Relationship between basic laboratory results and fibrosis in chronic hepatitis B patients. Viral Hepat J. 2019;25:45-49. doi: 10.4274/vhd.galenos.2019.2019.0010. DOI: https://doi.org/10.4274/vhd.galenos.2019.2019.0010

Demir NA, Kolgelier S, Ozcimen S, Gungor G, Sumer S, Demir LS, et al. Evaluation of the relation between hepatic fibrosis and basic laboratory parameters in patients with chronic hepatitis B fibrosis and basic laboratory parameters. Hepatitis Monthly. 2014;14(4). doi: 10.5812/hepatmon.16975. DOI: https://doi.org/10.5812/hepatmon.16975

Abdel-Aziz MM, Elshal MF, Abass AT, El-Kafrawy S, Ezzat S, Abdel-Wahab M. Comparison of AFP-L3 and p53 Antigen Concentration with Alpha-Fetoprotein as Serum Markers for Hepatocellular Carcinoma. Clin Lab J. 2016;62(6):1121-1129. doi: 10.7754/clin.lab.2015.151102. DOI: https://doi.org/10.7754/Clin.Lab.2015.151102

Xu Z, Shen J, Pan X, Wei M, Liu L, Wei K, et al. Predictive value of serum Golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection. J Med Virol. 2018;90(6):1053-1062. doi: 10.1002/jmv.25045. DOI: https://doi.org/10.1002/jmv.25045

Yao M, Wang L, Leung PS, Li Y, Liu S, Wang L, et al . The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review. Clin Rev Allergy Immunol. 2018;54:282-294. doi: 10.1007/s12016-017-8655-y. DOI: https://doi.org/10.1007/s12016-017-8655-y

Atilla A, Taşkın MH, Kazak Z, Aydın S, Kılıç SS. GP73 level in patients with chronic hepatitis B: relationship with liver biopsy, levels of ALT, AST and HBV DNA. Indian J Pathol Microbiol. 2022;65(1):55-58. doi: 10.4103/IJPM.IJPM_1149_20. DOI: https://doi.org/10.4103/IJPM.IJPM_1149_20

Zhou Q, Yan L, Du L, Tang X, Tang H. Combined serum Golgi membrane glycoprotein 73 improves the accuracy of transient elastography for significant fibrosis detection in patients with chronic HBV infections. Hepatitis Monthly. 2021;21(2). doi: 10.5812/hepatmon.102039. DOI: https://doi.org/10.5812/hepatmon.102039

Hailin B, Qun X. Study on the application value of HBV DNA, AFP and GP73 in the diagnosis of chronic hepatitis B severity and liver fibrosis. J Hainan Med Univ. 2019;25(9):700-703. doi: 10.13210/j.cnki.jhmu.20190510.003.

Gatselis NK, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S, et al. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients. World J Gastroenterol. 2020;26(34):5130. doi: 10.3748/wjg.v26.i34.5130. DOI: https://doi.org/10.3748/wjg.v26.i34.5130

Gu Y, Chen W, Zhao Y, Chen L, Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem. 2009;46(1):38-43. doi: 10.1258/acb.2008.008088 DOI: https://doi.org/10.1258/acb.2008.008088

Cao Z, Li Z, Wang Y, Liu Y, MoR, Ren P, et al. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat. 2017;24(Suppl 1):57–65. doi: 10.1111/jvh.12786. DOI: https://doi.org/10.1111/jvh.12786

Yan LB, Zhang QB, Zhu X, He M, Tang H. Serum S100 calcium binding protein A4 improves the diagnostic accuracy of transient elastography for assessing liver fibrosis in hepatitis B. Clinics Res Hepatol Gastroenterol. 2018;42(1):64-71. doi: 10.1016/j.clinre.2017.05.013. DOI: https://doi.org/10.1016/j.clinre.2017.05.013

Carpino G, Morini S, Corradini SG, Franchitto A, Merli M, Gaudio E, et al. Activated hepatic stellate cells in liver cirrhosis. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37(5):349-356. doi:10.1016/j.dId.2004.11009. DOI: https://doi.org/10.1016/j.dld.2004.11.009

Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, et al. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomarkers. 2012;11(4):161-171. doi: 10.3233/CBM-2012-00276. DOI: https://doi.org/10.3233/CBM-2012-00276

Badr EA, Korah TE, Ghani AA, El-Sayed S, Badr S. Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. Alexandria J Med. 2014;50(3):221-226.doi: 10.1016/j.ajme.2014.01.002. DOI: https://doi.org/10.1016/j.ajme.2014.01.002

Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, et al. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2020;111:334–342. doi: 10.1111/cas.14251. DOI: https://doi.org/10.1111/cas.14251

Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer. 2020;11(8):2008-2021. doi: 10.7150/jca.39972. DOI: https://doi.org/10.7150/jca.39972

Jia X, Gao Y, Zhai D, Liu J, Cai J, Wang Y, et al. Assessment of the clinical utility of glypican 3 as a serum marker for the diagnosis of hepatocellular carcinoma. Technol Cancer Res Treat. 2016;15:780-786. doi: 10.1177/1533034615605248. DOI: https://doi.org/10.1177/1533034615605248

Wang J, Zhang P, Liao J, Zhu Y, Liu X, Tang H. Association of α-fetoprotein levels with liver stiffness measurement in outpatients with chronic hepatitis B. Biosci Rep. 2021;41(1):BSR20203048. doi: 10.1042/BSR20203048. DOI: https://doi.org/10.1042/BSR20203048

Xia Y, Li Q, Gong L, Xu H, Pang L, Li Z, et al. Detection of hepatocellular carcinoma biomarker Golgi Protein 73 based on magnetic enzyme-linked immunoassay. J Nanosci Nanotechnol. 2017;17(1):231-237. doi: 10.1166/jnn.2017.12456. DOI: https://doi.org/10.1166/jnn.2017.12456

Abdel-Azeez HA, Sharaf SM, Elshamy EA, Fikry AA. Serum Golgi protein 73 as a biomarker for liver fibrosis in chronic hepatitis C patients. Egypt J Hospit Med. 2020;81(5):1993-2000. doi: 10.21608/ejhm.2020.124772. DOI: https://doi.org/10.21608/ejhm.2020.124772